Neurology: Volume 92, Number 16, April 16, 2019 Exam #1 - Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
About this course
- Released: 4/16/2019
- Expires: 4/16/2022
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF TROFINETIDE IN PEDIATRIC RETT SYNDROME
Upon completion of the article by Glaze et al, the participant should be able to:
- State what protein trofinetide is an analog to
- Discuss the most frequent treatment-related adverse effects observed in this study
- Discuss the types of efficacy end points in which significant treatment-related improvements were seen in this study
The article by Glaze et al covers the following core competency:
- Medical Knowledge
Refer to listing above the references in each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
AMA CREDIT DESIGNATION STATEMENT
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
James WM Owens Jr. MD, PhD receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology. Adam Kelly, MD, has served as a guest editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.
This CME program receives no commercial support.